NCT01439373 - Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 7, 2011

Primary Completion Date

December 5, 2011

Study Completion Date

December 5, 2011

Conditions

Hepatitis C, Chronic

Interventions

DRUG

GSK2336805

Active Investigational Drug

DRUG

Pegylated interferon alfa-2a

Standard of Care drug

DRUG

Ribavirin

Standard of Care drug

DRUG

GSK2336805 Matching Placebo

Placebo of Investigational Drug

Trial Locations (10)

GSK Investigational Site, Miramar

GSK Investigational Site, Tulsa

GSK Investigational Site, Houston

GSK Investigational Site, Las Vegas

GSK Investigational Site, Chula Vista

GSK Investigational Site, La Mesa

GSK Investigational Site, Oceanside

GSK Investigational Site, Coronado

GSK Investigational Site, Anaheim

GSK Investigational Site, San Juan